Corporate Presentation NASDAQ: HALO March 2023 1 Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2023) and expectations for profitability, revenue (including expectations for future royalties, milestones and product sales), EBITDA and earnings-per-share, and th ...

Fourth Quarter and Full Year 2022 Financial and Operating Results NASDAQ: HALO February 21, 2023 1 Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2023) and expectations for profitability, revenue (including expectations for future royalties, milestones and pro ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications Dr. Helen Torley - President and CEO Nicole LaBrosse - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Mike DiFiore - Evercore ISI Jason Butler - JMP Securities Jessica Fye - JPMorgan Corinne Jenkins - Goldman Sachs Vikram Purohit - Morgan Stanley Dan Tarjan - SVB Securities Oper ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered under Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value HALO The NASDAQ Stock Market, LLC For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For th ...

Halozyme Confidential and Proprietary Third Quarter 2022 Financial and Operating Results Nasdaq: HALO November 8, 2022 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2022) and expectations for profitability, revenue (including expectations for future milestone ...

First Quarter 2022 Financial Results Presentation May 10, 2022 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2022) and expectations for profitability, revenue (including expectations for future milestones and royalties), operating income, and earnings-per-sha ...

antares making medicines better" C Investor Presentation NASDAQ: ATRS | March 2022 Safe Harbor Statement & Non-GAAP Metrics This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forwardlooking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Compa ...

4Q and FY 2021 Financial and Operating Results NASDAQ: ATRS | March 3, 2022 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forwardlooking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Company's ability to achieve th ...

Halozyme Confidential and Proprietary 40th Annual J.P. Morgan Healthcare Conference Dr. Helen Torley, President and CEO January 10, 2022 Halozyme Confidential and Proprietary 2 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including financial estimates for 2021 and outlook for 2022) and expectations for ...

9 Halozyme Corporate Presentation November 2021 Forward-Looking Statements 2 In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2021) and expectations for profitability, revenue (including expectations for future milestones and royalty growth), operating income, cash flow, expenses and earn ...